Mengchu Wu – CEO, Health Genetech, Taiwan
Mengchu Wu, CEO of Health Genetech, introduces the innovative precision medicine company as it prepares to transition from a research-positioned provider to a healthcare partner. Wu goes on to offer…
Founded in 1994, Burrill & Company is a diversified global financial services firm focused on the life sciences industry. With $1.5 billion in assets under management, the firm’s businesses include venture capital/private equity, merchant banking, and media. By leveraging the scientific and business networks of its team, Burrill & Company has established unrivaled access and visibility in the life sciences industry. This unique combination of resources and capabilities enables the company to provide life sciences companies with capital, transactional support, management expertise, insight, market intelligence, and analysis through its investments, conferences, and publications. Headquartered in San Francisco, the company oversees a global network of offices throughout the United States, Latin America, Europe, and Asia.
G. Steven Burrill founded Burrill & Company as a logical extension of his 40-year involvement in the growth and prosperity of the biotechnology industry. Mr. Burrill has been an active advisor and catalyst in some of the industry’s most notable companies and transactions. Mr. Burrill’s close involvement and respected position within the industry has positioned the firm as a prominent deal-maker and facilitator of industry partnerships and alliances, all of which fosters a robust deal flow. Further contributing to this deal flow are: the scientific and business networks of its investment team; the Advisory Boards; the strategic and financial network of its limited partners; and the close relationships developed with numerous life science companies and management as a result of Burrill’s visibility, reputation, and the firm’s partnering and alliance work.
Mengchu Wu, CEO of Health Genetech, introduces the innovative precision medicine company as it prepares to transition from a research-positioned provider to a healthcare partner. Wu goes on to offer…
Today Su, CEO of Golden Biotechnology, introduces the innovative biotech developing a revolutionary botanical drug derived from the Taiwanese fungus Antrodia Camphorata. The company’s drug, Hocena®, has already received several…
Barry Lam, founder and chairman of Quanta Computer, shares the story of how he built the company into one of the world’s leading electronics and IT manufacturers. Lam then sheds…
With the USA and China locked in a trade war, China’s near neighbour Taiwan – with its strong scientific and technology base, political security and economic reliability – may stand…
Professor Shih-Hua Lin, president of Taiwan’s National Defense Medical Center, shares an overview of the academic and research environment of the institute as well as its role in cultivating the…
Scott Li, deputy director of H Spectrum, a biotech and talent incubator within the Foxconn group, explains the organization’s history and unique role in supporting Foxconn’s transition into healthcare. Li…
William Foreman, president of AmCham Taipei, describes the attractiveness and challenges of Taiwan’s business landscape and the implications of US-China relations on the island. Foreman goes on to highlight the…
Leo Liu, president of GeneReach Biotechnology Corp, shares the story of the diagnostics startup and explains his strategy to transition the company from a leading animal health point-of-care device manufacturer…
Susan Hsu, managing director of Taiwanese data-driven CRO StatPlus, speaks about the key trends impacting Taiwan’s clinical trial environment and goes on to share her views on the increasing attractiveness…
Tony Chung, CEO of Instant NanoBiosensors explains the potential of their fibre-optic biosensor technology – FOPPR, and the commercialization strategy for their light-sensing biomarker analyzer INB-D200. He also highlights Taiwan’s…
Shing-Mou Lee, founder and president of EMO Biomedicine, the leading CDMO provider of cell-based products in Taiwan, discusses the major regulatory and maturation trends in the region and shares his…
Tung-Mao Su, chairman of TPMA, highlights the association’s historic significance in cultivating Taiwan’s pharmaceutical industry, its members’ most pressing concerns, and outlines the developments of the company which he leads…
See our Cookie Privacy Policy Here
